Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Phase 4

• Conditions: Breast Cancer
• Interventions: Drug: Chidamide+ Fulvestrant

• Registration Number: NCT05191914
• Lead Sponsor: Liaoning Tumor Hospital & Institute

Brief Summary

The trial used a multicenter, open, single-arm design in which patients were treated with Chidamide combined with Fulvestrant.The primary objective is to evaluate the preliminary efficacy and safety of Chidamide in combination with Fulvestrant.Patients included in the trial were advanced breast cancer progressing on first-line aromatase inhibitor + Cyclin-dependent kinases（CDK）4/6i rescue therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-12-13
• Status Verified: 2022-01
• Study First Submitted QC: 2022-01-13
• Last Update Submitted: 2022-01-13
• Study First Posted: 2022-01-14
• Last Update Posted: 2022-01-14
• Study Start: 2022-02-07
• Primary Completion: 2022-07-30
• Study Completion: 2022-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

• age ≥ 18 years, postmenopausal * female patients;
• histologically or cytologically confirmed hormone receptor positive (ER positive, PR positive or negative), human epidermal growth factor receptor 2 negative # breast cancer patients;
• the disease before enrollment is overall unresectable locally advanced or metastatic breast cancer, and at least one measurable lesion or no measurable lesion and bone metastasis alone patients;
• for locally advanced or metastatic breast cancer, previous progression by first-line aromatase inhibitors combined with Cyclin-dependent kinases（CDK）4/6 inhibitors;
• the total number of regimens regardless of rescue therapy or adjuvant therapy before enrollment is ≤ 3, of which the number of rescue chemotherapy regimens is ≤ 1;
• Eastern Collaborative Oncology Group（ECOG） score 0-1;
• absolute neutrophil count ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, hemoglobin ≥ 90 g/L;
• expected survival time ≥ 3 months;
• Voluntarily participate in this clinical trial and sign the written informed consent form

Exclusion Criteria

• no measurable lesions (except simple bone metastasis), such as pleural or pericardial exudate, ascites, etc.;
• underwent major surgical procedures or significant trauma before enrollment, or patients are expected to undergo major surgical treatment;
• Patients who have previously been treated with fulvestrant or histone deacetylase inhibitors (including romidepsin, vorinostat), but have received only one cycle (≤ 2 times, d1, d15, respectively) of fulvestrant within 28 days (before enrollment) are allowed;
• known to have a history of allergy to the drug components of this protocol;
• the presence of brain (membrane) metastasis during the screening period;
• a history of immunodeficiency, including HIV test positive, or suffering from other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;
• uncontrolled important cardiovascular disease;
• abnormal liver function [total bilirubin > 1.5 times the upper limit of normal; alanine aminotrans（ALT）/aspartate aminotransferase（AST） > 2.5 times the upper limit of normal in patients without liver metastasis, alanine aminotrans（ALT）/aspartate aminotransferase（AST） > 5 times the upper limit of normal in patients with liver metastasis], abnormal renal function (serum creatinine > 1.5 times the upper limit of normal);
• pregnant, lactating female patients or women of childbearing potential baseline pregnancy test positive; or during the study and the last dose of at least 8 to take effective contraceptive measures in subjects of childbearing age;
• According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study (such as: severe hypertension, diabetes, thyroid disease, active infection, etc.);
• History of definite neurological or psychiatric disorders, including epilepsy or dementia;
• Unsuitable for participation in the study as judged by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
chidamide + fulvestrant	Chidamide+ Fulvestrant	-

Primary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS)	Up to approximately 16 months	PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause.

Secondary Outcome Measures

Name	Time	Method
Clinical Benefit Rate (CBR)	Up to approximately 16 months	Clinical benefit rate (CBR), defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1.
Duration of Response (DOR)	Up to approximately 16 months	Time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer as defined in RECIST 1.1.
Overall Response Rate (ORR)	Up to approximately 16 months	Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.
Overall Survival (OS)	Up to approximately 38 months	Time from date of randomization to the date of death from any cause.